Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, ove
Target Price
The average target price of SRZN is 36 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell